InDex Pharmaceuticals Holding AB (publ)
SSE:INDEX.ST
0.24 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | InDex Pharmaceuticals Holding AB (publ) |
Symbool | INDEX.ST |
Munteenheid | SEK |
Prijs | 0.244 |
Beurswaarde | 129,975,872 |
Dividendpercentage | 0% |
52-weken bereik | 0.198 - 0.926 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Johan Gileus |
Website | https://www.indexpharma.com |
An error occurred while fetching data.
Over InDex Pharmaceuticals Holding AB (publ)
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)